Resources.
Welcome to our Content Library for Neuroscience, Cannabinoid and Tryptamine Research.
When we find interesting articles and thought leadership that is relevant to synthetic biology, neuroscience, mental healthcare and the use of cannabinoids and psychedelics as therapeutics, we like to put it here.
RESEARCH WE’RE WATCHING
From the Journal of Psychopharmacology
Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine: Phenomenology, interpretation, and enduring effects.
This study characterized the subjective phenomena, interpretation, and persisting changes that people attribute to N,N-dimethyltryptamine-occasioned entity encounter experiences.
RESEARCH WE’RE WATCHING
From The Washington Post
A third of Americans now show signs of clinical anxiety or depression, Census Bureau finds amid coronavirus pandemic
A third of Americans are showing signs of clinical anxiety or depression, Census Bureau data shows, the most definitive and alarming sign yet of the psychological toll exacted by the coronavirus pandemic.
Research We’re Watching
From UC San Diego
The Psychedelic Science of Pain – Psychedelics and Health Research Initiative explores new territory in treating pain.
In the last few years, new research has demonstrated the powerful potential for classical psychedelics, especially psilocybin (the active compound in “magic mushrooms”), to treat a range of mental health disorders, including depression, anxiety and addiction.
Research We’re Watching
From Bioeconomy.xyz
Synthetic biology, the next revolution – You might have heard about synthetic biology and how the field is shaping up to become the next technology revolution. But what is it?
Putting it simply, synthetic biology is an engineering approach to biology. It involves the design and construction of biological parts to get them to do useful things inside cells.
Research We’re Watching
From The Psychedelic Renaissance
Psychedelics Inc. | Startups want to profit from psilocybin and LSD. They have the potential to heal millions.
Despite Covid-19, a crashing economy and formidable legal obstacles, a growing number of entrepreneurs and investors are betting that medicines derived from psychedelic drugs can become a real business and heal millions of people.
Research We’re Watching
From Forbes
Psychedelic Drugs Can Improve Quality Of Life – And Death – For Older Adults
Even before COVID-19 set off a global tsunami of anxiety and depression, psychedelic drugs were already showing exciting promise for treating these and other intractable mental health conditions.
Research We’re Watching
From BioSpace
Psychedelics Make a Comeback as Therapies for Brain Injury, PTSD, Anxiety and Even Addiction
PSYC, a new company formed by the holding company Global Trac Solutions Inc., is one of a handful of young companies and respected universities and research centers that are exploring the therapeutic potential of psychedelic drugs.
Research We’re Watching
From Visual Capitalist
Visualizing the Huge Potential of Minor Cannabinoids
CB Therapeutics is able to cost efficiently produce at scale, many of these “minor” cannabinoids that have major therapeutic potential but exist in very small concentrations in the plant making them costly to extract.
Research We’re Watching
From Mark Braunstein on Linkedin
Time for Addiction Treatment to Shift Views
CB Therapeutics is researching and developing molecules and compounds to advance Neuroscience and bring therapeutics to market to solve the opioid crisis, various addictions and mankind’s most challenging mental healthcare and social problems.
Research We’re Watching
From ABC Australia
Psychedelic therapy. A new paradigm for mental health.
Psychedelics are not addictive. In fact if you take them every day, within three days they stop working. And people know that. Most people use psychedelics once or twice in their life recreationally because they don’t need to anymore, but they can be powerful in ways of changing the way people think about things like other drugs that are much more addictive.
Research We’re Watching
From Scientific American
Psychedelics in Palliative Care
More and more research is being done on the efficacy of psilocybin, MDMA, DMT and other tryptamine compounds and their analogs for the treatment of some of mankind’s greatest mental healthcare and end of life challenges. CB Therapeutics is working hard to produce the therapeutics needed for clinical trials to address these challenges.
Research We’re Watching
From Vice News
Can a Trip-Free Psychedelic Still Help People With Depression?
Psilocybin has shown promise for conditions like depression. Now, researchers are asking if the psychedelic experience is absolutely necessary to treat mental health.A patient with depression once described their condition as “being enclosed in the most narrow confined space imaginable, it was like a sack over my head.” Another said it was as if he was locked in a metal cage “from the shoulders up,” or in a “mental prison.
